Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Shanu Modi
Person

Shanu Modi

Tracked across 1 events · 9 articles · First seen May 15, 2026 · Last active May 16, 2026

Sentiment
0
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 0
Tech
Enhertu FDA Approvals for Early Breast Cancer
Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has received two new approvals from the United States — Food and Drug Administration. These approvals are for the neoadjuvant…
Impact: Shanu Modi, a medical oncologist and principal investigator for the DESTINY-Breast11 trial, provided expert commentary on the significance of Trastuzumab deruxtecan's new indications for breast cancer treatment.
May 15, 2026 · 9 articles
NEWSDESK
Track Shanu Modi live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.